Confirmed Control Closed Transaction verified Cold RemediesConsumerConsumer Healthcare / OTC Cold RemediesNasal Cold RemedyOTC Healthcare

Zicam acquired by Church & Dwight

Church & Dwight acquired Zicam, an US consumer healthcare / otc cold remedies brand on Dec 1, 2020. The transaction value is shown as USD 530m. The current comp implies EV / revenue of 5.9x. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.

Transaction summary

Target
Zicam
Acquirer
Church & Dwight
Seller
-
Announced
2020-12-01
Geography
United States
Tags
Cold RemediesConsumerConsumer Healthcare / OTC Cold RemediesNasal Cold RemedyOTC Healthcare
Type
Acquisition
Deal type
Control
Stake acquired
-
First added
2026-06-19
Latest update
2026-06-19

Value and multiples

Price / value

USD 530M

Consideration | USD

Basis: Public source

EV / revenue

5.9x

Period not stated

Basis: FundComb estimate

EV / EBITDA

14.7x

EBITDA basis not stated

Basis: FundComb estimate

Basis

  • USD 530m consideration is treated as publicly disclosed or derived directly from public source data.
  • EV / revenue is shown as 5.9x based on the available comp inputs.
  • Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
  • EV / EBITDA is shown as 14.7x based on the available comp inputs.

Source summary

No public source summary has been published for this transaction yet.